A5111268352- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- Tuberculosis Research and Epidemiology
- Lymphoma Diagnosis and Treatment
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Inflammatory Bowel Disease
- Pharmaceutical studies and practices
- Musculoskeletal synovial abnormalities and treatments
- Gout, Hyperuricemia, Uric Acid
- Health Systems, Economic Evaluations, Quality of Life
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cytokine Signaling Pathways and Interactions
- Liver Disease Diagnosis and Treatment
- Toxin Mechanisms and Immunotoxins
- Bone health and osteoporosis research
- Urticaria and Related Conditions
- Liver Diseases and Immunity
- Bone Metabolism and Diseases
Carol Davila University of Medicine and Pharmacy
2016-2025
University of Iceland
2025
Institute for Rheumatic Diseases (Japan)
2013-2024
University of Bari Aldo Moro
2024
University of Bucharest
2023
Centre National d'Études Spatiales
2014-2023
Clinical Emergency Hospital Bucharest
2016-2023
A. O. Ordine Mauriziano di Torino
2023
Marmara University
2023
University of Turin
2023
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
Abstract Objective To evaluate the efficacy, including radiographic changes, and safety of etanercept methotrexate (MTX), used in combination alone, patients with rheumatoid arthritis (RA) whom previous treatment a disease‐modifying antirheumatic drug other than MTX had failed. Methods Patients RA were treated (25 mg subcutaneously twice weekly), oral (up to 20 or therapy plus through second year, double‐blinded manner. Clinical response was assessed using American College Rheumatology (ACR)...
<h3>Objectives</h3> Since the 2007 recommendations for management of early arthritis have been presented, considerable research has published in field arthritis, mandating an update European League Against Rheumatism (EULAR) arthritis. <h3>Methods</h3> In accordance with 2014 EULAR Standardised Operating Procedures, expert committee pursued approach that was based on evidence literature and opinion. The involved 20 rheumatologists, 2 patients 1 healthcare professional representing 12...
Background During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by presence of symptoms without clinically apparent synovitis. These are not well-characterised. This taskforce aimed define clinical characteristics with arthralgia who considered at risk for RA experts based on their experience. Methods The consisted 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and research fellow. process had three phases. In I, list...
Background JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare effectiveness four current second-line therapies RA with different modes action, since JAKi approval, an international collaboration 19 registers. Methods In this observational cohort study, patients initiating tumour necrosis factor inhibitors (TNFi), interleukin-6 (IL-6i), abatacept (ABA) or were included. compared these treatments terms...
Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic (PsA) has been established randomized clinical trials that have used improvement summated joint counts as an outcome. Whether joints at different anatomical locations might respond differentially to TNFi remains unknown. The aim the study was investigate potential variations responsiveness a first inhibitor among distinct treated routine care. Bionaive PsA from nine European countries...
Abstract Objective The Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) is a 3‐year, double‐blind, multicenter study evaluating the efficacy safety etanercept, methotrexate, combination etanercept plus methotrexate in patients active rheumatoid arthritis (RA). results after 1 2 years have been previously reported. Here we provide 3‐year clinical radiographic outcomes RA. Methods In this randomized, TEMPO study, 682 received 25 mg twice weekly, ≤20 or...
Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with IL-6 pathway can be directed at specific receptor using anti-IL-6Rα antibodies or by directly inhibiting cytokine. This paper is an update previous consensus document, based on most recent evidence and expert opinion, that aims to inform medical use interfering pathway. Methods A systematic literature research was performed focused...
Objective To compare the effectiveness of tocilizumab (TCZ) and tumour necrosis factor (TNF) inhibitors (TNFi) as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) patients rheumatoid arthritis (RA) after use at least one biologic DMARD (bDMARD). Methods We included RA having used bDMARD from 10 European registries. compared drug retention using Kaplan-Meier Cox models Clinical Disease Activity Index (CDAI) change over time mixed-effects...
Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi). Methods Data from 12 European registries, prospectively collected routine care, were pooled. TNFi (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Index (BASDAI) <40 mm Assessment of SpondyloArthritis International Society responses (ASAS 20/40) assessed at 6, 24...
RF and ACPA are used as diagnostic tools their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation effectiveness bDMARDs patients RA, using head-to-head comparisons a real-world setting.We conducted pooled analysis 16 observational RA registries. Inclusion criteria were diagnosis initiation treatment rituximab (RTX), abatacept (ABA), tocilizumab (TCZ) or TNF inhibitors (TNFis)...
Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare outcomes patients PsA treated TNFi and csDMARD comedication versus monotherapy.Patients from 13 European countries who initiated a first 2006-2017 were included. Country-specific comparisons of 1 year retention performed by status,...
The expanded therapeutic arsenal in rheumatoid arthritis (RA) raises new clinical questions. objective of this study is to compare the effectiveness cycling Janus kinase inhibitors (JAKi) with switching biologic disease-modifying antirheumatic drug (bDMARD) patients RA after failure first JAKi.This a nested cohort within data pooled from an international collaboration 17 national registries (JAK-pot collaboration). Data JAKi treatment and who were subsequently treated either second or bDMARD...
Objectives To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis (3) different European registries. Methods Real-life data from 13 registries participating the Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier log-rank test, Cox regression, χ² logistic regression...
Background:The primary objective of this study was to estimate depression’s prevalence in a cohort rheumatoid arthritis (RA) patients, and the secondary evaluate impact depression on disease activity over time. Methods: We included all patients with RA presenting our clinic from 2019 2020, who had three follow-up visits available. Depression calculated using patient’s history diagnosed depression, assessed score for 28 joints (DAS28) its components: tender joint count (TJC), swollen (SJC),...
In patients with axial spondyloarthritis (axSpA) initiating secukinumab, we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Index (BASDAI), well treatment continuation 12 months. From 11 European registries, axSpA, who initiated secukinumab in routine care, available data on 6-month ASDAS BASDAI...
Objective: The study aims to screen for depression and anxiety a real-life sample of RA patients observe whether phenotype characteristics disease activity measures are associated with anxiety. Methods: This cross-sectional screened using the PHQ9 HADS, self-reported questionnaires, all diagnosed that came their follow-up during one month. captured date diagnosis, pharmacological treatment, clinical examination, blood sampling, functional radiographic assessment. cut-off positive screening...
We aimed to compare various methods for imputing disease activity in longitudinally collected observational data of patients with axial spondyloarthritis (axSpA). conducted a simulation study on from 8583 axSpA ten European registries. Disease was assessed by the Axial Spondyloarthritis Activity Score (ASDAS) and corresponding low (LDA; ASDAS<2.1) state at baseline, 6 12 months. focused cross-sectional which impute missing values an individual particular time point based available...
Objective: This study aims to screen for depression and anxiety in a real-life sample of rheumatoid arthritis (RA) patients observe whether RA phenotype characteristics disease activity measures are associated with anxiety. Methods: cross-sectional from tertiary rheumatology hospital Romania screened all diagnosed that came their one month follow-up using the Patient Health Questionnaire-9 (PHQ9) Hospital Anxiety Depression Scale (HADS), self-reported questionnaires. The captured date...